AstraZeneca-Amgen Drug Achieves 69% Remission in Esophageal Disease Trial
Amgen and AstraZeneca said their asthma drug reduced swallowing difficulties and achieved disease remission in 69% of patients with a chronic inflammatory esophageal disorder.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.